Abbas Hussain Sells 5,682 Shares of Moderna (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) Director Abbas Hussain sold 5,682 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $46.63, for a total value of $264,951.66. Following the completion of the sale, the director directly owned 12,066 shares in the company, valued at $562,637.58. This trade represents a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Moderna Stock Down 1.2%

Shares of NASDAQ MRNA opened at $46.71 on Wednesday. The company has a market cap of $18.45 billion, a price-to-earnings ratio of -5.73 and a beta of 1.05. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $59.55. The stock has a 50-day moving average price of $51.77 and a two-hundred day moving average price of $39.60.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The company had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The company’s revenue for the quarter was up 260.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($2.52) earnings per share. As a group, analysts forecast that Moderna, Inc. will post -7.98 earnings per share for the current fiscal year.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Piper Sandler initiated/updated coverage with a buy/overweight stance, supplying fresh buy-side support that can lift sentiment and price targets for MRNA. Moderna (MRNA) Receives a Buy from Piper Sandler
• Positive Sentiment: Post?Q1 repricing: investors and some analysts are revisiting Q1 results, international delivery strength and late?stage pipeline/regulatory milestones (EU approvals, Phase 3 starts, upcoming U.S. PDUFA), which has driven analyst price?target bumps and buying interest. Moderna shares rise as investors revisit Q1 results, pipeline milestones, and fresh price-target bumps
• Positive Sentiment: RBC highlights continued progress across Moderna’s cancer vaccines and infectious?disease programs, reinforcing the pipeline narrative that underpins longer?term upside beyond COVID revenue. Moderna Sees Progress Across Cancer Vaccine, Infectious Disease Pipeline, RBC Says
• Neutral Sentiment: Director Abbas Hussain sold 5,682 shares under a pre?arranged Rule 10b5?1 plan (filing disclosed). Insider sales can be interpreted many ways; because this sale was planned it’s a neutral signal for most investors but may add short?term pressure. Moderna (NASDAQ:MRNA) Director Sells $264,951.66 in Stock
• Negative Sentiment: Brookline Capital Markets revised near?term EPS assumptions downward for several 2026 quarters (notably Q3/Q4) and adjusted FY2027 expectations — signaling continued earnings pressure and higher uncertainty around pace of margin recovery. That hurts short?term valuation. Moderna analyst estimate updates (Brookline Capital Markets)
• Negative Sentiment: Vertex terminated the partnered inhaled cystic fibrosis candidate after unresolved tolerability issues — a pipeline partnership setback that reduces near?term optionality and income from collaborations. Vertex drops Moderna-partnered inhaled cystic fibrosis candidate after unresolved tolerability issues

Institutional Investors Weigh In On Moderna

Several institutional investors and hedge funds have recently made changes to their positions in MRNA. AQR Capital Management LLC bought a new stake in shares of Moderna in the 1st quarter valued at $415,000. NewEdge Advisors LLC raised its stake in Moderna by 732.7% during the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock worth $328,000 after buying an additional 10,185 shares during the last quarter. United Services Automobile Association acquired a new position in Moderna in the first quarter valued at $230,000. Focus Partners Wealth boosted its position in Moderna by 58.7% during the first quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock valued at $668,000 after acquiring an additional 8,706 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in Moderna by 5.2% during the second quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock valued at $1,348,000 after acquiring an additional 2,410 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MRNA. Morgan Stanley set a $33.00 target price on shares of Moderna in a research note on Friday. Sanford C. Bernstein reissued a “market perform” rating and set a $45.00 price objective on shares of Moderna in a report on Tuesday, February 17th. BMO Capital Markets upgraded Moderna from a “market perform” rating to a “buy” rating in a research report on Monday, January 12th. The Goldman Sachs Group upped their target price on Moderna from $43.00 to $49.00 and gave the stock a “neutral” rating in a report on Friday. Finally, Piper Sandler lifted their price target on Moderna from $63.00 to $69.00 and gave the company an “overweight” rating in a research note on Monday, February 23rd. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $35.73.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.